NCT06641037View on ClinicalTrials.gov

A Study of LY3866288 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

October 17, 2024

Primary Completion Date

December 2, 2024

Study Completion Date

December 2, 2024

Conditions
Healthy
Interventions
DRUG

LY3866288

Administered orally

Trial Locations (1)

75247

Fortrea Clinical Research Unit, Dallas

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT06641037 - A Study of LY3866288 in Healthy Participants | Biotech Hunter | Biotech Hunter